Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Travere Therapeutics

Travere Therapeutics Receives Composite Rating Upgrade

The IBD SmartSelect Composite Rating for Travere Therapeutics rose from 94 to 96 Monday.

Investors Business Daily

Why Top 4% Stock Travere Therapeutics Skyrocketed To A Three-Year High

Shares of Travere Therapeutics shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug, Filspari.

Investors Business Daily

Travere Therapeutics Shows Rising Price Performance With Jump To 92 RS Rating

A Relative Strength Rating upgrade for Travere Therapeutics shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari

The U.S. Food and Drug Administration (FDA) on Wednesday approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for Travere Therapeutics, Inc.’s (NASDAQ:TVTX) Filspari (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist for IgA nephropathy (IgAN).

Benzinga

Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch

Travere Therapeutics shares rose Thursday after the FDA altered monitoring requirements for its drug, Filspari.

Investors Business Daily

Travere Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark

Travere Therapeutics sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

Travere Therapeutics Sees Relative Strength Rating Rise To 73

Travere Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Travere Therapeutics Draws Institutional Interest from Armistice Capital, Driehaus, and Wellington

Armistice Capital holds 8.9M shares in Travere Therapeutics as rare kidney disease stock climbs 110% following FILSPARI's full FDA approval.

International Business Times

Travere Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating

Travere Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

Investors Business Daily

IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why

Travere Therapeutics plummeted Friday after the FDA accepted its review application for a rare kidney disease drug — with one caveat.

Investors Business Daily

Travere Therapeutics Rallies To Buy Point As Kidney Drug Sales Rocket 182%; Anticipates FDA Priority Review For FSGS Treatment

Travere Therapeutics stock reported first quarter results on May 1. The company provides drugs to treat rare diseases.

Investors Business Daily

Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Investors Business Daily

Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles

The stock market is attempting to rebound amid President Donald Trump's trade war.

Investors Business Daily

IBD Stock Of The Day Travere Therapeutics: A Breakout And $1 Billion Opportunity Loom

Travere Therapeutics is Friday's IBD Stock Of The Day. The biotech stock is eyeing two potential entries and a second approval for Filspari.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug

Travere Therapeutics reached an agreement Tuesday on what data the FDA would require to approve its drug for a kidney disease.

Investors Business Daily

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level

Kidney disease leader Travere Therapeutics is pulling back to a key support level on the stock market today.

Investors Business Daily

Travere Therapeutics Hits 16-Month High On A Promising FDA 'Pivot' In Kidney Disease

Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.

Investors Business Daily

Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease

Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low

Travere said Thursday its kidney disease drug failed to pass muster in a confirmatory study, and TVTX stock crashed to a 10-year low.

Investors Business Daily

Travere Crashes 31% On A Potential Yearlong Delay For Its Kidney Disease Drug

Travere Therapeutics offered a disappointing update from a two-year study in kidney disease, and TVTX stock crashed Tuesday.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.